Methazolamide
From Wikipedia, the free encyclopedia
Methazolamide
|
|
Systematic (IUPAC) name | |
N-(3-Methyl-5-sulfamoyl-3H-1,3,4-thiadiazol-2-ylidene) ethanamide | |
Identifiers | |
CAS number | |
ATC code | S01 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C5H8N4O3S2 |
Mol. mass | 236.274 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Protein binding | 55% |
Metabolism | ? |
Half life | 14 hours |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
C(US) |
Legal status | |
Routes | Oral |
Methazolamide (Neptazane) is a carbonic anhydrase inhibitor.
[edit] References
- Iyer G, Bellantone R, Taft D (1999). "In vitro characterization of the erythrocyte distribution of methazolamide: a model of erythrocyte transport and binding kinetics.". J Pharmacokinet Biopharm 27 (1): 45–66. doi: . PMID 10533697.
- RxList. Neptazane. Retrieved on August 20, 2006.
- Shirato S, Kagaya F, Suzuki Y, Joukou S (1997). "Stevens-Johnson syndrome induced by methazolamide treatment.". Arch Ophthalmol 115 (4): 550–3. PMID 9109770.
- Skorobohach B, Ward D, Hendrix D (2003). "Effects of oral administration of methazolamide on intraocular pressure and aqueous humor flow rate in clinically normal dogs.". Am J Vet Res 64 (2): 183–7. doi: . PMID 12602587.
|